Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma

Alicia Furumaya, Belle V. van Rosmalen, R. Bart Takkenberg, Otto M. van Delden, Cornelis H. C. Dejong, Joanne Verheij, Thomas M. van Gulik

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Background: Transarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma. Methods: A systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment. Results: Eighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9%) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5%) patients. A significant decrease in tumour size from 9.79 ± 0.79 cm to 4.00 ± 1.36 cm (p < 0.001) was shown. Grade 3 complications occurred in 37/1284 (2.9%) patients. Surgical treatment was necessary in 35/1284 (2.7%) of patients. Conclusion: TAE/TAL appears to be a promising and safe treatment to decrease tumour size of hepatic haemangioma. The technique might also provide partial relief of symptoms, although no randomized clinical trials or prospective studies using validated QoL questionnaires are available. TAE/TAL may be considered as a viable alternative to resection.
Original languageEnglish
Pages (from-to)800-811
JournalCardioVascular and Interventional Radiology
Volume42
Issue number6
DOIs
Publication statusPublished - 15 Jun 2019
Externally publishedYes

Cite this

@article{cd52b5514f6449adb7ef9fce93888bfb,
title = "Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma",
abstract = "Background: Transarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma. Methods: A systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment. Results: Eighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9{\%}) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5{\%}) patients. A significant decrease in tumour size from 9.79 ± 0.79 cm to 4.00 ± 1.36 cm (p < 0.001) was shown. Grade 3 complications occurred in 37/1284 (2.9{\%}) patients. Surgical treatment was necessary in 35/1284 (2.7{\%}) of patients. Conclusion: TAE/TAL appears to be a promising and safe treatment to decrease tumour size of hepatic haemangioma. The technique might also provide partial relief of symptoms, although no randomized clinical trials or prospective studies using validated QoL questionnaires are available. TAE/TAL may be considered as a viable alternative to resection.",
author = "Alicia Furumaya and {van Rosmalen}, {Belle V.} and Takkenberg, {R. Bart} and {van Delden}, {Otto M.} and Dejong, {Cornelis H. C.} and Joanne Verheij and {van Gulik}, {Thomas M.}",
year = "2019",
month = "6",
day = "15",
doi = "10.1007/s00270-019-02169-x",
language = "English",
volume = "42",
pages = "800--811",
journal = "CardioVascular and Interventional Radiology",
issn = "0174-1551",
publisher = "Springer Verlag",
number = "6",

}

Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma. / Furumaya, Alicia; van Rosmalen, Belle V.; Takkenberg, R. Bart; van Delden, Otto M.; Dejong, Cornelis H. C.; Verheij, Joanne; van Gulik, Thomas M.

In: CardioVascular and Interventional Radiology, Vol. 42, No. 6, 15.06.2019, p. 800-811.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma

AU - Furumaya, Alicia

AU - van Rosmalen, Belle V.

AU - Takkenberg, R. Bart

AU - van Delden, Otto M.

AU - Dejong, Cornelis H. C.

AU - Verheij, Joanne

AU - van Gulik, Thomas M.

PY - 2019/6/15

Y1 - 2019/6/15

N2 - Background: Transarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma. Methods: A systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment. Results: Eighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9%) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5%) patients. A significant decrease in tumour size from 9.79 ± 0.79 cm to 4.00 ± 1.36 cm (p < 0.001) was shown. Grade 3 complications occurred in 37/1284 (2.9%) patients. Surgical treatment was necessary in 35/1284 (2.7%) of patients. Conclusion: TAE/TAL appears to be a promising and safe treatment to decrease tumour size of hepatic haemangioma. The technique might also provide partial relief of symptoms, although no randomized clinical trials or prospective studies using validated QoL questionnaires are available. TAE/TAL may be considered as a viable alternative to resection.

AB - Background: Transarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma. Methods: A systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment. Results: Eighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9%) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5%) patients. A significant decrease in tumour size from 9.79 ± 0.79 cm to 4.00 ± 1.36 cm (p < 0.001) was shown. Grade 3 complications occurred in 37/1284 (2.9%) patients. Surgical treatment was necessary in 35/1284 (2.7%) of patients. Conclusion: TAE/TAL appears to be a promising and safe treatment to decrease tumour size of hepatic haemangioma. The technique might also provide partial relief of symptoms, although no randomized clinical trials or prospective studies using validated QoL questionnaires are available. TAE/TAL may be considered as a viable alternative to resection.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85061742793&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30783780

U2 - 10.1007/s00270-019-02169-x

DO - 10.1007/s00270-019-02169-x

M3 - Review article

VL - 42

SP - 800

EP - 811

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 0174-1551

IS - 6

ER -